Polyplus-transfection Enters Reagent Deal with Roche Glycart

Jan 24, 2011

NEW YORK (GenomeWeb News) – Polyplus-transfection announced today it has granted a non-exclusive license to Roche Glycart for use of polyethylenimine for in vitro transfection applications for research purposes.

As a result, Roche Glycart will be able to use the transfection reagent to produce antibody-based products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Out of the Books

NPR reports that Turkish high school students will no longer study evolution.

Mountainside Sequencing

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

Better Treatments Sought

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

This Week in PNAS

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

Main menu